Therapeutic Response

EGFR oncogenic variants status confers therapeutic sensitivity to Osimertinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Osimertinib Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved osimertinib for reimbursement as a monotherapy treatment option as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
Tagrisso (osimertinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized osimertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGFR variants.